摘要
目的 通过前瞻性随机对照临床试验,探讨四环素、顺铂、氟美西诺(胞必佳)3种药物治疗非小细胞肺癌(NSCLC)恶性胸腔积液疗效和不良反应。方法 105例经组织学或细胞学确诊的NSCLC恶性胸腔积液患者胸水引流后,随机分为3组,胸腔内分别注入四环素500mg、顺铂100mg或胞必佳600μg,2周后复查胸片评价疗效。结果 105例患者胸腔注药后的总有效率为69.5％;四环素组有效率为73.5％,中位缓解期为7.3个月;顺铂组有效率为66.7％,中位缓解期为5.7个月;氟美西诺组有效率为68.6％,中位缓解期为7.1个月;3组有效率无统计学差异。治疗不良反应有不同程度发热、胸病及胃肠道反应,无骨髓抑制及肝肾损害。结论 四环素、顺铂、氟美西诺是治疗NSCLC恶性胸腔积液的有效药物,有效率相当,不良反应各异。
Objective This prospective randomized study is to evaluate the efficacy and side effect of pleural space perfusion with Tet-
racycline,Cisplatin (DDP) and Flumecinol (N-CWS) in treating malignant pleural effusion in non-small cell lung cancer (NSCLC)
patients. Method 105 NSCLC patients with malignant pleural effusion were randomized into three groups. group 1: Tetracycline
500mg, group 2:DDP 100mg, group 3: N-CWS 600mg. The three drugs were perfused into thoracic cavity after drainage of the pleu-
ral effusion. Efficacy was evaluated two weeks later by chest X-ray examination. Result The overall response rate was 69. 5% and
73. 5% for group 1, 66. 7% for group 2, 68. 6% for group 3 respectively. There is no statistically difference of response rate between
the three groups. The medium TTP was 7. 3 months for group 1, 5. 7 months for group 2, 7. 1 months for group 3. The main adverse
effects contain different degrees of fever, chest pain, and nausea, vomiting. There is no myelosuppression and damage of liver and kid-
ney function. Conclusion Pleural space perfusion with Tetracycline, DDP or N-CWS was effective in treating malignant pleural effu-
sion of NSCLC patients. The response rate had no difference statistically whereas the side effects showed some difference in three
groups.
出处
《广东药学》
2004年第4期46-49,共4页
Guangdong Pharmaceutical Journal
关键词
恶性胸腔积液
非小细胞肺癌
四环素
顺铂
氟美西诺
Malignant pleural effusion
Non-small cell lung cancer (NSCLC)
Tetracycline
cisplatin (DDP)
Flumecinol (NCWS)
